Alterations of mucosal microbiota in the colon of patients with inflammatory bowel disease revealed by real time polymerase chain reaction amplification of 16S ribosomal ribonucleic acid

Kabeerdoss, Jayakanthan; Jayakanthan, Prabavathi; Pugazhendhi, Srinivasan; Ramakrishna, B. S.

doi:10.4103/0971-5916.162091

Cited by 115 publications

(55 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In contrast to the previous statements that for patients with CD decrease in Firmicutes to Bacteroidetes ratio is typical 72 , in our study, the decreased serum vitD level was associated with more favorable microbiome of the gut of IBD patients.…”

contrasting

confidence: 99%

Seasonal changes of circulating 25-hydroxyvitamin D correlate with the lower gut microbiome composition in inflammatory bowel disease patients

Šoltýs

Stuchlíková

Hlavatý

et al. 2020

Sci Rep

View full text Add to dashboard Cite

Higher probability of the development of Crohn's disease (CD) and ulcerative colitis (UC) as a possible consequence of the north-south gradient has been recently suggested. Living far north or south of the equator is manifested in fluctuation of vitamin D (vitD) levels depending on the season in both healthy and affected individuals. In the present study we investigate the possible link between the seasonal serum vitD level to the microbial composition of the lower gut of Inflammatory Bowel disease (IBD) patients using 16S rRNA sequencing. Decrease of serum vitD level in winter/spring season in a cohort of 35 UC patients and 39 CD patients was confirmed. Low gut microbiota composition of patients with IBD correlated with the serum level of 25(OH)D that directly coupled to seasonal variability of the sunshine in the central European countries. It is supposed to be related to increased abundance of Actinobacteria and Proteobacteria in UC and Actinobacteria, Fusobacteria, Firmicutes and Bacteroidetes in CD. In summer/autumn period, we observed a reduction in abundance of bacterial genera typical for inflammation like Eggerthella lenta, Fusobacterium spp., Bacteroides spp., Collinsella aerofaciens, Helicobacter spp., Rhodococcus spp., Faecalibacterium prausnitzii; and increased abundance of Pediococcus spp. and Clostridium spp. and of Escherichia/Shigella spp. Inflammatory bowel disease (IBD) is a modern lifestyle disease with a worldwide prevalence. IBD involves mainly Crohn's disease (CD) and ulcerative colitis (UC) the etiology of which differs, so the clinical determination of the disease is difficult. Chronic inflammation of the gastrointestinal tract defined as cycling of the acute inflammation phase and remission is typical for IBD, both CD and UC. While in UC the disease is specifically localized to the colon with different degree of continuous inflammation proximally from the rectum, the CD can manifest anywhere in the gut. To date, there is no clear evidence of a single factor causing the IBD. It is affected by genetic susceptibility, microbiome composition, immune response dysregulation as well as various environmental factors 1. The vitD defficiency is common among IBD patients 2,3 and it has been speculated, that a low level of vitD might be one of the risk factors influencing the IBD 4-6. The current epidemiological studies of IBD show and upward dynamics in countries distant from the equator 7 , strongly suggesting a correlation between IBD incidence

show abstract

contrasting

confidence: 99%

Seasonal changes of circulating 25-hydroxyvitamin D correlate with the lower gut microbiome composition in inflammatory bowel disease patients

Šoltýs

Stuchlíková

Hlavatý

et al. 2020

Sci Rep

View full text Add to dashboard Cite

show abstract

“…This ratio is often used as a proxy for microbial health status (40)(41)(42)(43)(44)(45) and, more specifically, to describe the degree of dysbiosis in IBD (43)(44)(45). Of note, the phylum-level population shifts from Bacteroidetes to Firmicutes induced by DSS in our study resemble those observed in obese individuals and in animals on a high-fat diet and have been associated with low-grade intestinal and systemic inflammation in obesity (46,47).…”

Section: Discussionsupporting

confidence: 62%

Ursodeoxycholic Acid and Its Taurine- or Glycine-Conjugated Species Reduce Colitogenic Dysbiosis and Equally Suppress Experimental Colitis in Mice

Bossche

Hindryckx

Devisscher

et al. 2017

Appl Environ Microbiol

112

View full text Add to dashboard Cite

The promising results seen in studies of secondary bile acids in experimental colitis suggest that they may represent an attractive and safe class of drugs for the treatment of inflammatory bowel diseases (IBD). However, the exact mechanism by which bile acid therapy confers protection from colitogenesis is currently unknown. Since the gut microbiota plays a crucial role in the pathogenesis of IBD, and exogenous bile acid administration may affect the community structure of the microbiota, we examined the impact of the secondary bile acid ursodeoxycholic acid (UDCA) and its taurine or glycine conjugates on the fecal microbial community structure during experimental colitis. Daily oral administration of UDCA, tauroursodeoxycholic acid (TUDCA), or glycoursodeoxycholic acid (GUDCA) equally lowered the severity of dextran sodium sulfate-induced colitis in mice, as evidenced by reduced body weight loss, colonic shortening, and expression of inflammatory cytokines. Illumina sequencing demonstrated that bile acid therapy during colitis did not restore fecal bacterial richness and diversity. However, bile acid therapy normalized the colitis-associated increased ratio of Firmicutes to Bacteroidetes. Interestingly, administration of bile acids prevented the loss of Clostridium cluster XIVa and increased the abundance of Akkermansia muciniphila, bacterial species known to be particularly decreased in IBD patients. We conclude that UDCA, which is an FDA-approved drug for cholestatic liver disorders, could be an attractive treatment option to reduce dysbiosis and ameliorate inflammation in human IBD.IMPORTANCE Secondary bile acids are emerging as attractive candidates for the treatment of inflammatory bowel disease. Although bile acids may affect the intestinal microbial community structure, which significantly contributes to the course of these inflammatory disorders, the impact of bile acid therapy on the fecal microbiota during colitis has not yet been considered. Here, we studied the alterations in the fecal microbial abundance in colitic mice following the administration of secondary bile acids. Our results show that secondary bile acids reduce the severity of colitis and ameliorate colitis-associated fecal dysbiosis at the phylum level. This study indicates that secondary bile acids might act as a safe and effective drug for inflammatory bowel disease.

show abstract

“…Gophna et al [11], and Bibiloni et al [12] showed a significant increase of Bacteroidetes in CD than in UC patients. However, in an Indian population, Kabeerdoss et al [13] found greater Bacteroides and Lactobacillus concentration in inflamed colonic mucosa of patients with UC in comparison to CD patients.…”

Section: Introductionmentioning

confidence: 99%

Intestinal Bacteria Composition and Translocation of Bacteria in Inflammatory Bowel Disease

et al. 2017

View full text Add to dashboard Cite

BackgroundLive commensal intestinal bacteria are present in the peripheral blood where they can induce inflammation.ObjectiveTo evaluate the intestinal bacteria composition and translocation of bacteria in IBD.MethodsBoth blood and tissue biopsy samples were collected from adult patients with active/inactive Crohn’s disease (CD), active/inactive ulcerative colitis (UC) and healthy individuals. Most of the patients were newly diagnosed and none of them received antibiotics. Using a reverse transcription–quantitative real-time PCR (RT-qPCR) method, we determined the composition of microbiota. NOD2/CARD15 genotyping was also studied.ResultsTotal bacterial DNA concentration was increased in tissue and blood samples of IBD patients compared to healthy controls. Furthermore, the active IBD cases had higher total bacterial DNA concentration levels compared to the inactive cases. Three species characterized dysbiosis in IBD, namely an increase of Bacteroides spp in active and inactive IBD samples, and a decrease in Clostridium leptum group (IV), and Faecalibacterium prausnitzi in both active and inactive IBD patients. No significant association between bacterial translocation and NOD2/CARD15 mutations was found.ConclusionsThe composition of the microbiota in IBD patients differs from that of healthy controls. The high rate of bacterial DNA in the blood samples indicates translocation in inflammatory bowel disease.

show abstract

Alterations of mucosal microbiota in the colon of patients with inflammatory bowel disease revealed by real time polymerase chain reaction amplification of 16S ribosomal ribonucleic acid

Cited by 115 publications

References 29 publications

Seasonal changes of circulating 25-hydroxyvitamin D correlate with the lower gut microbiome composition in inflammatory bowel disease patients

Seasonal changes of circulating 25-hydroxyvitamin D correlate with the lower gut microbiome composition in inflammatory bowel disease patients

Ursodeoxycholic Acid and Its Taurine- or Glycine-Conjugated Species Reduce Colitogenic Dysbiosis and Equally Suppress Experimental Colitis in Mice

Intestinal Bacteria Composition and Translocation of Bacteria in Inflammatory Bowel Disease

Contact Info

Product

Resources

About